预测与预防小于胎龄儿:来自SPREE与ASPRE研究的证据
本研究基于两项多中心研究数据,探讨孕早期筛查子痫前期对小于胎龄儿(SGA)的预测价值及阿司匹林预防SGA的效果。SPREE研究显示联合筛查高风险组涵盖约46%的<37周SGA和56%的<32周SGA,筛查阳性率12.2%。ASPRE试验中阿司匹林使<37周SGA发生率降低约40%、<32周降低约70%,对≥37周SGA无显著影响。
要点
- 孕早期联合筛查子痫前期高风险组涵盖约46%的<37周SGA和56%的<32周SGA,筛查阳性率12.2%。
- ASPRE试验中阿司匹林使<37周SGA发生率降低约40%、<32周降低约70%,≥37周无显著影响。
- 阿司匹林降低SGA主要源于子痫前期妊娠中SGA减少,<37周降低约70%、<32周降低约90%。
核心结论
- 孕早期联合筛查子痫前期可识别大部分早产SGA病例,高风险组预防性使用阿司匹林可预防这些SGA。
研究设计与样本
- 数据来自两项多中心研究:SPREE研究在孕11-13周联合母体特征与生物标志物筛查子痫前期;ASPRE试验将联合筛查为早产子痫前期高风险(>1/100)的单胎妊娠妇女随机分配至阿司匹林150 mg/日(孕11-14周至36周)或安慰剂组。
诊断标准与关键数值
- SPREE研究中联合母体因素、平均动脉压、子宫动脉搏动指数和血清胎盘生长因子筛查早产子痫前期,高风险组涵盖约46%的<37周SGA(<10th百分位)和56%的<32周SGA,总体筛查阳性率12.2%(2014/16451例妊娠)。
- ASPRE试验中阿司匹林使<37周SGA(<10th百分位)总体发生率降低约40%,<32周降低约70%;≥37周SGA发生率无显著影响。
- 阿司匹林相关SGA发生率下降主要见于子痫前期妊娠,<37周SGA降低约70%、<32周降低约90%。
- 基于上述结果估计,孕早期筛查早产子痫前期并在高风险组使用阿司匹林可能使早产SGA和早期SGA发生率分别降低约20%和40%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To examine the effect of first-trimester screening for pre-eclampsia (PE) on the prediction of delivering a small-for-gestational-age (SGA) neonate and the effect of prophylactic use of aspirin on the prevention of SGA.
METHODS: The data for this study were derived from two multicenter studies. In SPREE, we investigated the performance of screening for PE by a combination of maternal characteristics and biomarkers at 11-13 weeks' gestation. In ASPRE, women with a singleton pregnancy identified by combined screening as being at high risk for preterm PE (> 1 in 100) participated in a trial of aspirin (150 mg/day from 11-14 until 36 weeks' gestation) compared to placebo. In this study, we used the data from the ASPRE trial to estimate the effect of aspirin on the incidence of SGA with birth weight < 10th , < 5th and < 3rd percentile for gestational age. We also used the data from SPREE to estimate the proportion of SGA in the pregnancies with a risk for preterm PE of > 1 in 100.
RESULTS: In SPREE, screening for preterm PE by a combination of maternal factors, mean arterial pressure, uterine artery pulsatility index and serum placental growth factor identified a high-risk group that contained about 46% of SGA neonates < 10th percentile born at < 37 weeks' gestation (preterm) and 56% of those born at < 32 weeks (early); the overall screen-positive rate was 12.2% (2014 of 16 451 pregnancies). In the ASPRE trial, use of aspirin reduced the overall incidence of SGA < 10th percentile by about 40% in babies born at < 37 weeks' gestation and by about 70% in babies born at < 32 weeks; in babies born at ≥ 37 weeks, aspirin did not have a significant effect on incidence of SGA. The aspirin-related decrease in incidence of SGA was mainly due to its incidence decreasing in pregnancies with PE, for which the decrease was about 70% in babies born at < 37 weeks' gestation and about 90% in babies born at < 32 weeks. On the basis of these results, it was estimated that first-trimester screening for preterm PE and use of aspirin in the high-risk group would potentially reduce the incidence of preterm and early SGA by about 20% and 40%, respectively.
CONCLUSION: First-trimester screening for PE by the combined test identifies a high proportion of cases of preterm SGA that can be prevented by the prophylactic use of aspirin. © 2018 Crown copyright. Ultrasound in Obstetrics & Gynecology © 2018 ISUOG.
引用
- Tan MY, Poon LC, Rolnik DL, et al. Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE. Ultrasound Obstet Gynecol. 2018. PMID: 29704277. doi:10.1002/uog.19077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。